Joint News Release Media Inquiries: Contact DIEM Labs, LLC Contact BASF Cai Berg Tony Graetzer CEO Communications Nutrition & Health, North America cai@bergimport.com tony.graetzer@partners.basf.com +1-734 277 3629 +1-201-704-2670

BASF to enter medical foods market in the US with DIEM Labs

ANN ARBOR, MI, and FLORHAM PARK, NJ, November 3, 2017 – BASF Corporation and

DIEM Labs, LLC. have entered into a distribution agreement to commercialize BASF’s first

U.S. medical food product for the dietary management of patients with Non-Alcoholic Fatty

Liver Disease (NAFLD).

As part of this agreement, BASF will use its scientific expertise and state-of-the-art

manufacturing capabilities to provide a first-to-the-market medical food product to patients

with NAFLD. DIEM Labs will market the product to health care professionals in the U.S. and

sell it through an online hub. The product will be available to U.S. patients, who are under the

supervision of a physician for NAFLD management.

Rising NAFLD rates present a looming large-scale health challenge in America

NAFLD is defined as fat accumulated in the liver, representing more than 5 percent of its

weight. This condition has an estimated prevalence of 20 to 30 percent in the western

population, and is closely linked to obesity and metabolic syndrome. Diagnosis often starts

with abnormal liver function test results or detection of hepatic steatosis during incidental

imaging. If the condition is not managed, it can progress to more severe liver damage such

as fibrosis and cirrhosis. By managing the condition at an early stage, called “simple

steatosis,” the disease can be controlled. Currently, there is no dedicated product available

on the market specifically targeting patients with NAFLD, and patients are left with no

solution to improve their condition other than undergo extensive lifestyle changes.

BASF acknowledged the significant unmet need and developed a new medical food product

for the dietary management of patients with NAFLD. A product-specific human intervention

trial including more than 170 patients has been conducted by BASF to show that the product

is effective and safe in the dietary management of patients with NAFLD. The to-be-launched

product will therefore add to the current standard of care for NAFLD. It is anticipated that it

will be commercially available throughout the U.S. in the first half of 2018.

Growing relevance of the space between human nutrition and pharma

Specially formulated foods are increasingly used as part of the overall management regimen

for certain diseases or associated conditions and play a vital role in supporting a patient’s

nutrient requirements.

“With this step, BASF is entering an attractive new market segment in the space between

human nutrition and pharma,” said François Scheffler, head of BASF’s Global Human

Nutrition and Pharma Solutions Businesses. “This further supports our mission to enable

people to live a healthy and fulfilling life.”

“We are delighted to work together with such a renowned company as BASF in the medical

foods market,” said Cai Berg, CEO of DIEM labs. “The new product will offer a solution to

patients who currently have no other alternative than lifestyle modifications to turn their

NAFLD around.”

BASF, one of the market leaders in the human nutrition industry, offers a broad portfolio of

essential nutrients under the Newtrition® brand. With extensive experience in both the

nutrition and pharma industry, BASF uses its capabilities and competencies to offer new

solutions for emerging health issues.

About BASF At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The approximately 114,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into five segments: Chemicals, Performance Products, Functional Materials & Solutions, Agricultural Solutions and Oil & Gas. BASF generated sales of about €58 billion in 2016. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (BAS). Further information at www.basf.com.

About DIEM Labs Diem Labs is a specialized medical food company committed to providing clinicians and consumers with clinically validated solutions for underserved and emerging health conditions. Formed by an international partnership of scientists, producers, and veterans of the US healthcare industry, Diem Labs is driven to supply safe and effective nutritional products that are supported by rigorous scientific

evidence and meet the highest quality standards. Diem Labs’ directors bring over 60 years of combined experience serving practitioners and patients through physician-direct and consumer-direct channels. Through strategic partnerships and proprietary development expertise, Diem Labs is dedicated to providing healthcare practitioners, patients and consumers with exclusive, effective solutions that address common challenges not met by products currently available in the healthcare marketplace.